Skip to main content
ISTH 2023 Main banner
Back

    Poster Networking

    COVID

    Poster Networking Session

    PB0094 - Antiphospholipid antibodies in severe and critically ill COVID-19 patients

    Sunday, June 25, 2023
    18:30 – 19:30 ET
    Room: Exhibition

      Co-Author(s)

    • Jamilya Khizroeva, MD

      Professor of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

      • Presenting Author(s)

    • AM

      Alexander Makatsariya

      Head of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

      • Co-Author(s)

    • VB

      Victoria Bitsadze

      Professor of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • MT

      Maria Tretyakova

      professor of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • AS

      Antonina Solopova

      Professor of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • AV

      Alexander Vorobev

      Professor of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • AM

      Alexander Mischenko

      Professor of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • BB

      Baigalmaa Baldansambuu

      Postgraduate student of the Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • DD

      Daria Doronicheva

      Resident doctor of the Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • GK

      Grigoreva Kristina

      Assistant of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • Nilufar Gashimova, Postgraduate

      Postgraduate student of Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • DZ

      Diana Zabolotnaya

      Resident doctor of the Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • DB

      David Blbulyan

      Resident doctor of the Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    • KK

      Kamilla Khalieva

      Student of the Obstetrics, gynecology and perinatal medicine Department
      I.M.Sechenov First Moscow State Medical University
      Moscow, Moskva, Russia

    Background: Since the first months of the pandemic, many works have appeared demonstrating the circulation of antiphospholipid antibodies (aPLA) in covid patients. Subsequent repeated testing showed that these antibodies are more transient, and their connection with thrombotic phenomena remains controversial. Nevertheless, there was a significant difference in the prevalence of aPLA between survived and non-survived COVID19 patients in the intensive care unit which justifies the need for further studies.

    Aims: to find out the possible relationship of aPLA with a severe course and an unfavorable outcome of the COVID19.

    Methods: ELISA detection of antibodies to cardiolipin (CL), b2GPI, annexin-V, prothrombin (PT) and phosphatidylserine-prothrombin (PS-PT) antibodies, isotypes IgG and IgM.

    Results: 106 severe and critically ill COVID-19 patients were tested, of which 15 survived and 91 died. Of the 91 survived patients IgM isotype of the following antibodies were detected: abs to CL were in 14 (15.4%), to b2GPI – in 13 (14.3%), to PS-PT - 13 (14.3%), to ANX-V – 7 (7.7%). Among total 106 patients, 12 (11.3%) developed thrombosis, with arterial (5.7%) and venous (5.7%) equally distributed. Of the 12 patients with thrombosis, the different aPLA were distributed as follows: abs to CL - in 4 cases (IgM), to b2GPI – 3 (IgG), 3 (IgM), to anx-V – 1 (IgM), to PS-PT -3 (IgM), to Pt – 1 (IgM).
    Interestingly, IgM prevailed mainly, which indicates the formation of de NOVO antibodies.

    Conclusion(s): We did not detect a large number of aPL, as expected before the examination. However, the presence of antibodies was significantly higher in the group of non-surviving patients. Despite the absence of a clear relationship between the presence of aPL and microthrombosis, the presence of aPL may have contributed to the widespread microvascular thrombosis observed in patients with COVID-19.